Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
Bruno Fernando BuzoJessica Fernandes RamosRenata Ariza Marques RossettiNanci SallesAlfredo Mendrone-JúniorVanderson Geraldo RochaAna Catharina de Seixas Santos NastriPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2020)
To sum up, HBV serology, ALT, and HBV-DNA monitoring are essential to detect hepatic flares earlier, even in populations with chronic inactive hepatitis, due to the possibility of later seroconversion. HBV infection was not related to increased 2-year mortality post-transplant. Antiviral prophylaxis did not cause any important clinical or laboratory side effects that could demand discontinuation, and its use was not associated with later neutrophil and platelet engraftments.